115 related articles for article (PubMed ID: 9627740)
21. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
22. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2.
Pham DQ; Plakogiannis R
Ann Pharmacother; 2005 Dec; 39(12):2065-72. PubMed ID: 16288072
[TBL] [Abstract][Full Text] [Related]
23. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
Lerner V; Kaptsan A; Miodownik C; Kotler M
Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
[TBL] [Abstract][Full Text] [Related]
24. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses.
Sajjad SH
Int Clin Psychopharmacol; 1998 Jul; 13(4):147-55. PubMed ID: 9727725
[TBL] [Abstract][Full Text] [Related]
25. The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects.
McCreadie RG; MacDonald E; Wiles D; Campbell G; Paterson JR
Br J Psychiatry; 1995 Nov; 167(5):610-7. PubMed ID: 8564316
[TBL] [Abstract][Full Text] [Related]
26. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
27. Lack of effect of vitamin E on serum creatine phosphokinase in patients with long-term tardive dyskinesia.
Dorevitch A; Lerner V; Shalfman M; Kalian M
Int Clin Psychopharmacol; 1997 May; 12(3):171-3. PubMed ID: 9248874
[TBL] [Abstract][Full Text] [Related]
28. Treatment of tardive dyskinesia.
Egan MF; Apud J; Wyatt RJ
Schizophr Bull; 1997; 23(4):583-609. PubMed ID: 9365997
[TBL] [Abstract][Full Text] [Related]
29. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E.
Elkashef AM; Wyatt RJ
Schizophr Bull; 1999; 25(4):731-40. PubMed ID: 10667743
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of tardive oculogyric spasms with vitamin E.
Coupland N; Nutt O
J Clin Psychopharmacol; 1995 Aug; 15(4):285-6. PubMed ID: 7593713
[No Abstract] [Full Text] [Related]
31. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
Shamir E; Barak Y; Shalman I; Laudon M; Zisapel N; Tarrasch R; Elizur A; Weizman R
Arch Gen Psychiatry; 2001 Nov; 58(11):1049-52. PubMed ID: 11695951
[TBL] [Abstract][Full Text] [Related]
32. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence.
Cavallaro R; Regazzetti MG; Mundo E; Brancato V; Smeraldi E
Neuropsychopharmacology; 1993 May; 8(3):233-9. PubMed ID: 8099483
[TBL] [Abstract][Full Text] [Related]
33. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
[TBL] [Abstract][Full Text] [Related]
34. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
Soares-Weiser K; Rathbone J
Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of melatonin in tardive dyskinesia.
Castro F; Carrizo E; Prieto de Rincón D; Rincón CA; Asián T; Medina-Leendertz S; Bonilla E
Invest Clin; 2011 Sep; 52(3):252-60. PubMed ID: 21950196
[TBL] [Abstract][Full Text] [Related]
36. The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia.
Sachdev P; Saharov T; Cathcart S
Biol Psychiatry; 1999 Dec; 46(12):1672-81. PubMed ID: 10624549
[TBL] [Abstract][Full Text] [Related]
37. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.
Emsley R; Niehaus DJ; Koen L; Oosthuizen PP; Turner HJ; Carey P; van Rensburg SJ; Maritz JS; Murck H
Schizophr Res; 2006 May; 84(1):112-20. PubMed ID: 16632329
[TBL] [Abstract][Full Text] [Related]
38. Managing antipsychotic-induced tardive dyskinesia.
Gardos G
Drug Saf; 1999 Feb; 20(2):187-93. PubMed ID: 10082074
[TBL] [Abstract][Full Text] [Related]
39. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia.
Brown K; Reid A; White T; Henderson T; Hukin S; Johnstone C; Glen A
Biol Psychiatry; 1998 Jun; 43(12):863-7. PubMed ID: 9627739
[TBL] [Abstract][Full Text] [Related]
40. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
